recent posts

banner image

Dr Reddy`s Miryalaguda facility gets 3 USFDA observations


Dr Reddy's Laboratories said the US health regulator has made three observations after completing inspection of its Miryalaguda facility. "The audit of the company's Active Pharmaceutical Ingredients (API) manufacturing plant at Miryalaguda, by the United States Food and Drug Administration (USFDA), has been completed on February 21, 2017," Dr Reddy's Laboratories said in a filing to BSE.

Dr Reddy`s Miryalaguda facility gets 3 USFDA observations Dr Reddy`s Miryalaguda facility gets 3 USFDA observations Reviewed by Ripples Advisory Private Limited on February 22, 2017 Rating: 5

No comments:

Note: only a member of this blog may post a comment.

Stay Connected

Powered by Blogger.